Study Finder

Only clinical trials help to reliably ascertain how to improve efficacy, while collecting data on the impact of adverse effects. Every well-conducted study, every participating site and patient contribute to an advanced care for tumor patients.

If you are interested in participating in a study, please don’t hesitate to contact us.

STUDY
INDICATION
STATUS
FOR CENTERS
FOR PATIENTS

INDICATION

Urogenital tumors

Renal Cell Carcinoma

metastatic / locally advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

INDICATION

Multiple Myeloma ≥ 2nd line

THERAPY

carfilzomib + lenalidomide + dexamethasone or CAR/DEX

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

INDICATION

Lung Cancer

stage IV non-squamous NSCLC or extensive-stage SCLC

1st line

THERAPY

atezolizumab + platin-based induction chemotherapy, atezolizumab-based maintenance therapy

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

INDICATION

Breast Cancer

Indication for pegfilgrastim

Non-Hodgkin-Lymphoma

Indication for pegfilgrastim

NHL: 1st line BC: early-stage

THERAPY

pegfilgrastim (Neulasta®) + CTx

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

INDICATION

Lung Cancer

NSCLC, stage II - IV

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

INDICATION

Multiple Myeloma 1st line

THERAPY

lenalidomide (Revlimid®) + dexamethasone

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

INDICATION

Breast Cancer

HR-positive / HER2-negative, inoperable or metastatic

≥ 1st line

THERAPY

1st line: palbociclib + aromatase inhibitor (letrozole / anastrozole / exemestane) or fulvestrant
≥ 2nd line: palbociclib + letrozole or fulvestrant

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

INDICATION

Breast Cancer

HER2/neu-negative, metastatic or locally advanced

2nd line

THERAPY

fulvestrant + AZD2014

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

INDICATION

Multiple Myeloma 1st line, 2nd line

THERAPY

no specification

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

INDICATION

Lung Cancer

NSCLC, metastatic / advanced and inoperable

1st line

THERAPY

nab-paclitaxel + carboplatin

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

INDICATION

Breast Cancer

metastatic / locally advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Open

FOR PATIENTS

Open

STATUS

Recruitment

INDICATION

Lung Cancer

NSCLC, metastatic or locally advanced, EGFR-mutation

after progression on EGFR-TKI therapy or 1st-line with EGFR T790 M mutation

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

INDICATION

Multiple Myeloma

advanced

3rd line

THERAPY

pomalidomide + dexamethasone

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

INDICATION

Breast Cancer

bone metastases

Prostate Cancer

bone metastases

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

INDICATION

Urogenital tumors

advanced, metastatic

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

INDICATION

Lung Cancer

NSCLC: stage IIIb, IV

Pancreatic Cancer

stage III/IV, advanced

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

INDICATION

Urogenital tumors

metastatic / locally advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

INDICATION

DLBCL

diffuse large B-cell lymphoma (DLBCL)
untreated, CD20-positive

1st line

THERAPY

Rixathon® (rituximab biosimilar) + CHOP

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

INDICATION

Breast Cancer

HR-positive / HER2-negative, with visceral metastases, postmenopausal

1st line

THERAPY

ribociclib + aromatase inhibitor vs. paclitaxel +/- bevacizumab

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

INDICATION

Colorectal Cancer

metastatic

THERAPY

trifluridine / tipiracil (Lonsurf®)

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment

INDICATION

Breast Cancer

metastatic / locally advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

INDICATION

Colorectal Cancer

metastatic / advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Treatment

INDICATION

Lymphatic Neoplasia

Non-Hodgkin-Lymphoma, Chronic lymphocytic leukaemia, Multiple Myeloma
aggressive, indolent

1st line, 2nd line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

INDICATION

Pancreatic Cancer

metastatic / advanced and inoperable

1st line

THERAPY

no specification

FOR CENTERS

Closed

FOR PATIENTS

Closed

STATUS

Follow-Up

INDICATION

Colorectal Cancer

metastatic, RAS wild-type

1st line

THERAPY

panitumumab + FOLFIRI or FOLFOX

FOR CENTERS

Closed

FOR PATIENTS

Open

STATUS

Recruitment